Matrix metalloproteinases: Novel targets for directed cancer therapy

Drugs and Aging

Volumn 11, Issue 3, 1997, Pages 229-244

  Yu, Anita E ^a   Hewitt, Robert E ^a   Connor, Edward W ^a   Stetler Stevenson, William G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; BE 16627B; COLLAGENASE; CYTOKINE; ELASTASE; GELATINASE; GROWTH FACTOR; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CARTILAGE DEGENERATION; CELL DIVISION; CLINICAL TRIAL; DRUG DESIGN; DRUG TARGETING; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; MORPHOGENESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; REVIEW; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; TISSUE DEGENERATION; WOUND HEALING;

EID: 0030755044     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199711030-00006     Document Type: Review

References (144)

1. Stetler-Stevenson WG, Brown PD, Onisto M, et al. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 1990; 265: 13933-8
2. Poulsom R, Pignatelli M, Stetler-Stevenson WO, c. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992; 141: 389-96
3. Grignon DJ, Sakr W, Toth M, et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996; 56: 1654-9
4. Terada T, Okada Y, Nakanuma Y. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 1996; 23: 1341-4
5. Hollstein M, Soussi T, Thomas G, et al. P53 gene alterations in human tumors: perspectives for cancer control. Recent Results Cancer Res 1997; 143: 369-89
6. McDonnell TJ, Navone NM, Troncoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer [see comments]. J Urol 1997; 157: 569-74
7. Vinante F, Vassanelli A, Zanotti R, et al. Circulating levels of soluble CD23 reflect clinical and biological features of leukemic B-cell chronic lymphoproliferative disorders. Int J Clin Lab Res 1995; 25: 189-94
8. Sarfati M, Chevret S, Chastang C, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996; 88: 4259-64
9. Zinzani PL, Buccini C, Zaccaria A, et al. Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma. Eur J Haematol 1996; 57: 335-40
10. Liotta LA, Abe S, Robey PC, et al. Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor. Proc Natl Acad Sci USA 1979; 76: 2268-72
11. Drewa G, Zbytniewski Z, Kanclerz A. Activity of some lysosomal hydrolases in the homogenates of transplantable melanotic and amelanotic melanoma in golden hamster (Mesocricetus auratus, Waterhouse). Arch Geschwulstforsch 1978; 48: 198-201
12. Poole AR, Tiltman KJ, Recklies AD, et al. Differences in secretion of the proteinase cathepsin B at the edges of human breast carcinomas and fibroadenomas. Nature 1978; 273: 545-7
13. Stetler-Stevenson WG, Aznovoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9: 541-73
14. Shintani S, Alcalde RE, Matsumara T, et al. Extracellular matrices expression in invasion area of adenoid cystic carcinoma of salivary glands. Cancer Lett 1997; 116: 9-14
15. Jaspars LH, Bonnet P, Bloemena E, et al. Extracellular matrix and beta 1 integrin expression in nodal and extranodal T-cell lymphomas. J Pathol 1996; 178: 36-43
16. Liotta LA. Tumor invasion and metastases - role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res 1986; 46: 1-7
17. Urbanski SJ, Edwards DR, Maitland A, et al. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 1992; 66: 1188-94
18. Corcoran ML, Kleiner DE, Stetler-Stevenson WG. Regulation of matrix metalloproteinases during extracellular matrix turnover. Adv Exp Med Biol 1995; 385: 151-9; discussion 179-84
19. Kossakowska AE, Huchcroft SA, Urbanski SJ, et al. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer 1996; 73: 1401-8
20. Seiki M. Membrane type-matrix metalloproteinase and tumor invasion. Curr Top Microbiol Immunol 1996; 213: 23-32
21. Costello PC, Del Maestro RF, Stetler-Stevenson WG. Gelatinase A expression in human malignant gliomas. Ann N Y Acad Sci 1994; 732: 450-2
22. Emmert-Buck MR, Roth MJ, Zhuang Z, et al. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol 1994; 145: 1285-90
23. Grigioni WF, D'Errico A, Fiorentino M, et al. Gelatinase A (MMP-2) and its mRNA detected in both neoplastic and stromal cells of tumors with different invasive and metastatic properties. Diagn Mol Pathol 1994; 3: 163-9
24. Polette M, Gilbert N, Stas I, et al. Gelatinase A expression and localization in human breast cancers: an in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch 1994; 424: 641-5
25. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994; 7: 2062-72
26. Stetler-Stevenson WG. Progelatinase A activation during tumor cell invasion. Invasion Metastasis 1994; 14: 259-68
27. Cawston TE, Galloway WA, Mercer E, et al. Purification of rabbit bone inhibitor of collagenase. Biochem J 1981; 195: 159-65
28. Levi E, Fridman R, Miao HQ, et al. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci U S A 1996; 93: 7069-74
29. Ochieng J, Fridman R, Nangia-Makker P, et al. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 1994; 33: 14109-14
30. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells [see comments]. Nature 1994; 370: 61-5
31. Will H, Hinzmann B. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem 1995; 231: 602-8
32. Imai K, Ohuchi E, Aoki T, et al. Membrane-type matrix metalloproteinase I is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2. Cancer Res 1996; 56: 2707-10
33. Kinoshita T, Sato H, Takino T, et al. Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase. Cancer Res 1996;56:2535-8
34. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 1990; 87: 5578-82
35. Libson AM, Gittis AG, Collier IE, et al. Crystal structure of the haemopexin-like C-terminal domain of gelatinase A [letter]. Nat Struct Biol 1995; 2: 938-42
36. Murphy G, Allan JA, Willenbrock F, et al. The role of the C-terminal domain in collagenase and stromelysin specificity. J Biol Chem 1992; 267: 9612-8
37. Bode W. A helping hand for collagenases: the haemopexin-like domain. Structure 1995; 3: 527-30
38. Murphy G, Nguyen Q, Cockett MI, et al. Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem 1994; 269: 6632-6
39. Murphy G, Willenbrock F, Ward RV, et al. The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases [published erratum appears in Biochem J 1992 Jun 15; 284 Pt 3: 935]. Biochem J 1992; 283: 637-41
40. Strongin AY, Collier IE, Krasnov PA, et al. Human 92 kDa type IV collagenase: functional analysis of fibronectin and carboxyl-end domains. Kidney Int 1993; 43: 158-62
41. Ward RV, Atkinson SJ, Reynolds JJ, et al. Cell surface-mediated activation of progelatinase A: demonstration of the involvement of the C-terminal domain of progelatinase A in cell surface binding and activation of progelatinase A by primary fibroblasts. Biochem J 1994; 304: 263-9
42. Emmert-Buck MR, Emonard HP, Corcoran ML, et al. Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex. FEBS Lett 1995; 364: 28-32
43. Kleiner DE, Unsworth EJ, Krutzsch HC, et al. Higher-order complex formation between the 72-kilodalton type IV collagenase and tissue inhibitor of metalloproteinases-2. Biochemistry 1992; 31: 1665-72
44. Greene J, Wang M, Liu YE, et al. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996; 271: 30375-80
45. Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 1995; 270: 14313-8
46. Murphy G, Houbrechts A, Cockett MI, et al. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity [published erratum appears in Biochemistry 1991 Oct 22; 30 (42): 103621. Biochemistry 1991; 30: 8097-102
47. Williamson RA, Martorell G, Carr MD, et al. Solution structure of the active domain of tissue inhibitor of metalloproteinases-2: a new member of the OB fold protein family. Biochemistry 1994; 33: 11745-59
48. Willenbrock F, Crabbe T, Slocombe PM, et al. The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A. Biochemistry 1993; 32: 4330-7
49. Ura H, Bonfil RD, Reich R, et al. Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogene-transformed human bronchial epithelial cells. Cancer Res 1989; 49: 4615-21
50. Thorgeirsson UP, Liotta LA, Kalebic T, et al. Effect of natural protease inhibitors and a chemoattractant on tumor cell invasion in vitro. J Natl Cancer Inst 1982; 69 (5): 1049-54
51. Schultz RM, Silberman S, Persky B, et al. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 1988; 48 (19): 5539-45
52. Alvarez OA, Carmichael DF, DeClerck YA. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 1990; 82 (7): 589-95
53. DeClerck YA, Yean TD, Chan D, et al. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res 1991; 51 (8): 215 1-7
54. Albini A, Melchiori A, Santi L, et al. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991 ; 83 (11): 775-9
55. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the over-expression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 1994; 86: 299-304
56. Tsuchiya Y, Sato H, Endo Y, et al. Tissue inhibitor of metalloproteinase 1 is a negative regulator of the metastatic ability of a human gastric cancer cell line, KKLS, in the chick embryo. Cancer Res 1993; 53: 1397-402
57. Kawamata H, Kawai K, Kameyama S, et al. (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int J Cancer 1995; 63: 680-7
58. Otani Y, Okazaki I, Arai M, et al. Gene expression of interstitial collagenase (matrix metalloproteinase 1) in gastrointestinal tract cancers. J Gastroenterol 1994; 29: 391-7
59. Gray ST, Yun K, Motoori T, et al. Interstitial collagenase gene expression in colonie neoplasia. Am J Pathol 1993; 143: 663-71
60. Polette M, Clavel C, Muller D, et al. Detection of mRNAs encoding collagenase I and stromelysin 2 in carcinomas of the head and neck by in situ hybridization. Invasion Metastasis 1991; 11: 76-83
61. Gray ST, Wilkins RJ, Yun K. Interstitial collagenase gene expression in oral squamous cell carcinoma. Am J Pathol 1992; 141: 301-6
62. Wolf C, Chenard MP, Durand de Grossouvre P, et al. Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. J Invest Dermatol 1992;94:870-2
63. Pyke C, Ralfkiaer E, Tryggvason K, et al. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 1993; 142: 359-65
64. Gress TM, Muller-Pillasch F, Lerch MM, et al. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62: 407-13
65. Boag AH, Young ID. Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma: demonstration by immunohistochemistry and in situ hybridization. Am J Pathol 1994; 144: 585-91
66. Davies B, Waxman J, Wasan H, et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993; 53: 5365-9
67. Pyke C, Ralfkiaer E, Huhtala P, et al. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res 1992; 52: 1336-41
68. Davies B, Miles DW, Happerfield LC, et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993; 67: 1126-31
69. Autio-Harmainen H, Karttunen T, Hurskainen T, et al. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest 1993; 69: 312-21
70. Canete-Soler R, Litzky L, Lubensky I, et al. Localization of the 92 kd gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridization. Am J Pathol 1994; 144: 518-27
71. Nielsen BS, Timshel S, Kjeldsen L, et al. 92kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 1995; 65: 57-62
72. Muller D, Wolf C, Abecassis J, et al. Increased stromelysin 3 gene squamous cell carcinomas. Cancer Res 1993; 53: 165-9
73. Rouyer N, Wolf C, Chenard MP, et al. Stromelysin-3 gene expression in human cancer: an overview. Invasion Metastasis 1995; 14: 269-75
74. Newell KJ, Willy JP, Rodgers WH, et al. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 1994; 10: 199-206
75. McDonnell S, Navre M, Coffey Jr RJ, et al. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog 1991; 4: 527-33
76. Pajouh MS, Nagle RB, Breathnach R, et al. Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 1991; 117: 144-50
77. Nomura H, Sato H, Seiki M, et al. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995; 55: 3263-6
78. Okada A, Bellocq JP, Rouyer N, et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci U S A 1995; 92: 2730-4
79. Ohtani H, Motohashi H, Sato H, et al. Dual over-expression pattern of membrane-type metalloproteinase-1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoclectron microscopy. Int J Cancer 1996; 68: 565-70
80. Noel A, Munaut C, Nusgens B, et al. Different mechanisms of extracellular matrix remodeling by fibroblasts in response to human mammary neoplastic cells. Invasion Metastasis 1993; 13: 72-81
81. Noel AC, Polette M, Lewalle J-M, et al. Coordinate enhancement of gelatinase A mRNA and activity levels. Int J Cancer 1994; 56: 331-6
82. Biswas C. Collagenase stimulation in cocultures of human fibroblasts and human tumor cells. Cancer Lett 1984; 24: 201-7
83. Kataoka H, DeCastro R, Zucker S, et al. Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDn gelatinase. Cancer Res 1993; 53: 3154-8
84. Biswus C, Zhang Y, DeCastro R, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55: 434-9
85. Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res 1989; 49: 2533-53
86. Van Der Stappen JWJ, Hendriks T, Wobbes T. Correlation between collagenolytic activity and grade of histological differentiation incolorectal tumours. Int J Cancer 1990; 45: 1071-8
87. Murray GI, Duncan ME, O'Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996; 2: 461-2
88. Daidone MG, Silvestrini R, D'Errico A, et al. Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer 1991; 48: 529-32
89. Grigioni WH, Garbisa S, D'Errico A, et al. Evaluation of hepatocellular carcinoma aggressiveness by a panel of extracellular matrix antigens. Am J Pathol 1991; 138: 647-54
90. Garbisa S, Scagliotti G, Masiero L, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992; 52: 4548-9
91. Brown PD, Bloxidge RE, Stuart NS, et al. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 1993; 85: 574-8
92. Brown PD, Bloxidge RE, Anderson E, et al. Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis 1993; 11: 183-9
93. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 1994; 218: 325-9
94. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991; 51(18 Suppl.): 5054S-9S
95. Liotta LA, Stetler-Stevenson WG, Steeg PS. Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Invest 1991; 9: 543-51
96. Mignatti P, Tsuboi R, Robbins E, et al. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989; 108: 671-82
97. Johnson MD, Kim HR, Chesler L, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994; 160: 194-202
98. Schnaper HW, Grant DS, Stetler-Stevenson WG, et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in virto. J Cell Physiol 1993; 156: 235-46
99. Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61
100. Vincenti MP, Clark IM, Brinckerhoff CE. Using inhibitors of metalloproteinases to treat arthritis: easier said than done? [see comments]. Arthritis Rheum 1994; 37: 1115-26
101. Karran EH, Young TJ, Markwell RE, et al. In vivo model of cartilage degradation - effects of a matrix metalloproteinase inhibitor. Ann Rheum Dis 1995; 54: 662-9
102. Harper GP. Use of collagenase inhibitors in the treatment of demyelinating diseases. Eur Patent 1991; 423: 943
103. McMillan JI, Weeks R, West JW, et al. Pharmacological inhibition of gelatinase B induction and tumor cell invasion. Int J Cancer 1996; 67: 523-31
104. Watson SA, Morris TM, Parsons SL, et al. Therapeutic effect of the matrix metalloproteinase inhibitor, batimaslat, in a human colorectal cancer ascites model. Br J Cancer 1996; 74: 1354-8
105. Henderson B, Davies DE. The design of inhibitors of cartilage breakdown, osteoarthritis. In: Russell RGG, Dieppe PA, editors. Osteoarthritis: current research and prospects for pharmacological intervention. London: IBC Technical Services, 1991: 203-16
106. Brown PD. Clinical trials of a low molecular weight matrix metalloproteinase inhibitor in cancer. Ann N Y Acad Sci 1994; 732: 217-21
107. Darlak K, Moiller RB, Stack S, et al. Thiol-based inhibitors of mammalian collagenase. J Biol Chem 1990; 265: 5199-205
108. Odake S, Morita Y, Morikawa T, et al. Inhibition of matrix metalloproteinases by peptidyl hydroxamic acids. Biochem Biophys Res Commun 1994; 199: 1442-6
109. Broadhurst MJ, Handa BK, Johnson WH, et al. Phosphinic acid derivatives. Eur Patent 1988; 276: 436
110. Hunter DJ, Marwell RE, Ward RW. Peptides with collagenase inhibiting activity. Eur Patent 1989; 320: 118
111. Markwell RE, Rahman SS, Ward RW. Phosphonopeptides with collagenase inhibiting activity. World Patent 1991; 91: 15506
112. Markwell RE, Ward RW, Ratcliffe SJ. Phosphonopeptides with collagenase inhibiting activity. World Patent 1991; 91: 15507
113. Roberts WH, Borkakoti NA, Johnson N. Collagenase inhibitors: their design and therapeutic use. J Enzyme Inhib 1987; 2: 1-22
114. Seed M, Ismaiel S, Cheung CY, et al. Inhibition of interleukin I beta induced rat and human cartilage degradation in vitro by the metalloproteinase inhibitor U2739. Ann Rheum Dis 1993; 52: 37-43
115. Nixon J, Bottomley KM, Broadhurst MJ, et al. Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro. Int J Tissue React 1991; 3: 237-41
116. Andrews HJ, Plumpton TA, Harper GP, et al. A synthetic peptide metalloproteinase inhibitor, but not TIMP. prevents the breakdown of proteoglycan within articular cartilage in vitro. Agents Actions 1992; 37: 147-54
117. Williamson RA, Martorell G, Carr MD, et al. Solution structure of the active domain of tissue inhibitor of metalloproteinases-2: a new member of the OB fold protein family. Biochemistry 1994; 33: 11745-59
118. Dhanaraj V, Ye QZ, Johnson LL, et al. X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure 1996; 4: 375-86
119. Van Doren SR, Kurochkin AV, Hu W, et al. Solution structure of the catalytic domain of human stromelysin complexed with a hydrophobic inhibitor. Protein Sci 1995; 4: 2487-98
120. Lovejoy B, Cleasby A, Hassell AM, et al. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science 1994; 263: 375-7
121. Gohlke U, Gomis-Ruth FX, Crabbe T, et al. The C-terminal (haemopexin-like) domain structure of human gelatinase A (MMP2): structural implications for its function. FEBS Lett 1996; 378: 126-30
122. Stams T, Spurlino JC, Smith DL, et al. Structure of human neutrophil collagenase reveals large S1' specificity pocket. Nat Struct Biol 1994; 1: 119-23
123. Gomis-Ruth FX, Grams F, Yiallouros I, et al. Crystal structures, spectroscopic features, and catalytic properties of cobalt(II), copper(II), nickel(II), and mercury(II) derivatives of the zinc endopeptidase astacin: a correlation of structure and proteolytic activity. J Biol Chem 1994; 269: 17111-7
124. Eccles SA, Box GM, Court WJ, et al. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996; 56: 2815-22
125. Taraboletti G, Garofalo A, Belotti D, et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995; 87: 293-8
126. Watson SA, Morris TM, Robinson G, et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995; 55: 3629-33
127. Wang X, Fu X, Brown PD, et al. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994; 54: 4726-8
128. Chirivi RG, Garofalo A, Crimmin MJ, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994; 58: 460-4
129. B Biotech/Tanabe pact on marimastat. Scrip 1996 Nov 22; 2183: 8
130. Naito K, Kanbayashi N, Nakajima S, et al. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Im J Cancer 1994; 58: 730-5
131. Tressler RJ, Wee J, Summers B, et al. Galardin, a potent metalloproteinase inhibitor, prolongs survival time in a B16-F10 melanoma experimental metastasis model [abstract]. Clin Exp Metastasis 1994; 12: 28
132. Anderson IC, Shipp MA, Docherty AJ, et al. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 1996; 56: 715-8
133. Stetler-Stevenson WG, Krutzsch HC, Wacher MP, et al. The activation of human type IV collagenase proenzyme: sequence identification of the major conversion product following organomercurial activation. J Biol Chem 1989; 264: 1353-6
134. Stetler-Stevenson WG, Talano JA, Gallagher ME, et al. Inhibition of human type IV collagenase by a highly conserved peptide sequence derived from its prosegment. Am J Med Sci 1991; 302: 163-70
135. Melchiori A, Albini A, Ray JM, et al. Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment. Cancer Res 1942; 52: 2353-6
136. Benelli R, Adatia R, Ensoli B, et al. Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy. Oncol Res 1994; 6: 251-7
137. Muir D. Metalloproteinase-dependent neurite outgrowth within a synthetic extracellular matrix is induced by nerve growth factor. Exp Cell Res 1994; 210: 243-52
138. Ghosh SS. Dipeptide-analog-based metalloendopeptidase inhibitors and methods of using the same. World Patent 1991; 91: 05763
139. Ghosh SS, Mobashery S. N-acyl peptide metalloproteinase inhibitors and methods of using the same. World Patent 1991; 91: 05555
140. Wallace DA, Bates SRE, Walker B, et al. Competitive inhibition of human skin collagenase by N-benzyloxycarbonyl-L-prolyl-L-alanyl-3-amino-oxopropyl-L-leucyl-L-alanylglycine ethyl ester. Biochem J 1986; 239: 797-9
141. Greenwald RA, Moak SA, Ramamurthy NS, et al. Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and, in combination with flurbiprofen, ameliorate bone damage. J Rheumatol 1992; 19: 927-38
142. Bols M. Inhibition of collagenase by aranciamycin and aranciamycin derivatives. J Med Chem 1992; 35: 2768-71
143. Golub LM, McNamara TF, D'Angelo G, et al. A non-bacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987; 66: 1310-4
144. Tanaka T, Metori K, Mineo S, et al. Studies on collagenase inhibitors: II. Inhibitory effects of anthraquinones on bacterial collagenase. J Pharm Soc Jpn 1990; 110: 688-92